AVCNF
Price
$0.17
Change
-$0.00 (-0.00%)
Updated
Sep 25 closing price
Capitalization
21.28M
BIOYF
Price
$8.50
Change
-$0.00 (-0.00%)
Updated
Sep 25 closing price
Capitalization
96.09M
Interact to see
Advertisement

AVCNF vs BIOYF

Header iconAVCNF vs BIOYF Comparison
Open Charts AVCNF vs BIOYFBanner chart's image
Avicanna
Price$0.17
Change-$0.00 (-0.00%)
Volume$76.95K
Capitalization21.28M
BioSyent
Price$8.50
Change-$0.00 (-0.00%)
Volume$200
Capitalization96.09M
AVCNF vs BIOYF Comparison Chart in %
Loading...
AVCNF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BIOYF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AVCNF vs. BIOYF commentary
Sep 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AVCNF is a StrongBuy and BIOYF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 26, 2025
Stock price -- (AVCNF: $0.17 vs. BIOYF: $8.50)
Brand notoriety: AVCNF and BIOYF are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: AVCNF: 107% vs. BIOYF: 13%
Market capitalization -- AVCNF: $21.28M vs. BIOYF: $96.09M
AVCNF [@Pharmaceuticals: Generic] is valued at $21.28M. BIOYF’s [@Pharmaceuticals: Generic] market capitalization is $96.09M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.86B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AVCNF’s FA Score shows that 0 FA rating(s) are green whileBIOYF’s FA Score has 1 green FA rating(s).

  • AVCNF’s FA Score: 0 green, 5 red.
  • BIOYF’s FA Score: 1 green, 4 red.
According to our system of comparison, BIOYF is a better buy in the long-term than AVCNF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AVCNF’s TA Score shows that 4 TA indicator(s) are bullish while BIOYF’s TA Score has 5 bullish TA indicator(s).

  • AVCNF’s TA Score: 4 bullish, 5 bearish.
  • BIOYF’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, BIOYF is a better buy in the short-term than AVCNF.

Price Growth

AVCNF (@Pharmaceuticals: Generic) experienced а -7.36% price change this week, while BIOYF (@Pharmaceuticals: Generic) price change was -2.05% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +2.88%. For the same industry, the average monthly price growth was +23.85%, and the average quarterly price growth was +67.10%.

Industries' Descriptions

@Pharmaceuticals: Generic (+2.88% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BIOYF($96.1M) has a higher market cap than AVCNF($21.3M). BIOYF YTD gains are higher at: 11.220 vs. AVCNF (-15.007). BIOYF has higher annual earnings (EBITDA): 12M vs. AVCNF (-495.6K). BIOYF has more cash in the bank: 20.4M vs. AVCNF (208K). AVCNF has less debt than BIOYF: AVCNF (37.1K) vs BIOYF (942K). BIOYF has higher revenues than AVCNF: BIOYF (39.5M) vs AVCNF (25.4M).
AVCNFBIOYFAVCNF / BIOYF
Capitalization21.3M96.1M22%
EBITDA-495.6K12M-4%
Gain YTD-15.00711.220-134%
P/E RatioN/A16.57-
Revenue25.4M39.5M64%
Total Cash208K20.4M1%
Total Debt37.1K942K4%
FUNDAMENTALS RATINGS
AVCNF vs BIOYF: Fundamental Ratings
AVCNF
BIOYF
OUTLOOK RATING
1..100
7825
VALUATION
overvalued / fair valued / undervalued
1..100
62
Fair valued
26
Undervalued
PROFIT vs RISK RATING
1..100
10042
SMR RATING
1..100
9942
PRICE GROWTH RATING
1..100
8858
P/E GROWTH RATING
1..100
10060
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BIOYF's Valuation (26) in the null industry is somewhat better than the same rating for AVCNF (62). This means that BIOYF’s stock grew somewhat faster than AVCNF’s over the last 12 months.

BIOYF's Profit vs Risk Rating (42) in the null industry is somewhat better than the same rating for AVCNF (100). This means that BIOYF’s stock grew somewhat faster than AVCNF’s over the last 12 months.

BIOYF's SMR Rating (42) in the null industry is somewhat better than the same rating for AVCNF (99). This means that BIOYF’s stock grew somewhat faster than AVCNF’s over the last 12 months.

BIOYF's Price Growth Rating (58) in the null industry is in the same range as AVCNF (88). This means that BIOYF’s stock grew similarly to AVCNF’s over the last 12 months.

BIOYF's P/E Growth Rating (60) in the null industry is somewhat better than the same rating for AVCNF (100). This means that BIOYF’s stock grew somewhat faster than AVCNF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AVCNFBIOYF
RSI
ODDS (%)
Bullish Trend 1 day ago
85%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
45%
Momentum
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
38%
MACD
ODDS (%)
Bearish Trend 4 days ago
83%
Bearish Trend 1 day ago
45%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
37%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
40%
Advances
ODDS (%)
N/A
Bullish Trend 18 days ago
47%
Declines
ODDS (%)
Bearish Trend 10 days ago
85%
Bearish Trend 8 days ago
40%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 3 days ago
56%
Aroon
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 1 day ago
33%
View a ticker or compare two or three
Interact to see
Advertisement
AVCNF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BIOYF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
EMNSF2.13N/A
N/A
Elementis PLC
NEXPF5.51N/A
N/A
NEXI S.P.A.
RBGPF76.43N/A
N/A
Reckitt Benckiser Group Plc.
PGNT5.23-0.02
-0.42%
Paragon Technologies, Inc.
HAIVF3.49-0.15
-4.25%
HAIVISION SYS INC .

AVCNF and

Correlation & Price change

A.I.dvisor tells us that AVCNF and PRFX have been poorly correlated (+20% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AVCNF and PRFX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AVCNF
1D Price
Change %
AVCNF100%
+1.68%
PRFX - AVCNF
20%
Poorly correlated
-6.71%
ARSUF - AVCNF
12%
Poorly correlated
N/A
BSPK - AVCNF
9%
Poorly correlated
-6.90%
APNHY - AVCNF
7%
Poorly correlated
-6.64%
BKUH - AVCNF
5%
Poorly correlated
N/A
More

BIOYF and

Correlation & Price change

A.I.dvisor tells us that BIOYF and BUDZ have been poorly correlated (+6% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BIOYF and BUDZ's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIOYF
1D Price
Change %
BIOYF100%
N/A
BUDZ - BIOYF
6%
Poorly correlated
-3.23%
AVCNF - BIOYF
1%
Poorly correlated
+1.68%
APNHY - BIOYF
0%
Poorly correlated
-6.64%
BSPK - BIOYF
0%
Poorly correlated
-6.90%
BIOVF - BIOYF
0%
Poorly correlated
N/A
More